Venous thromboembolism prevention through the use of novel Factor Xa inhibitors

ABSTRACT

The risk of a venous thromboembolic event is not limited to the pre-hospital, hospital, or immediate post-hospital period. Because of challenges with data collection, the risk of venous thromboembolism (VTE) up to 3 months post-hospitalization for patients with acute and serious medical problems in the setting of chronic disease and/or risk factors for VTE is probably under reported. The growing acceptance and indications of direct oral anticoagulants (DOACs) now includes an indication for VTE prevention for one of the Factor Xa agents. In this paper, the authors explore the issue of VTE in the extended post-hospital period and strategies to provide protection from these morbid and potentially mortal events with oral anticoagulants.

KEYWORDS:

• Venous thromboembolism
• hospitals
• guidelines
• risk factors

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. A peer reviewer on this manuscript is involved in clinical studies of different anticoagulant drugs (includingDOACs) in different indications. They also got honoraria from different companies active in the field of anticoagulation (including DOACs) for educational lectures and talks.

Additional information

Funding

This manuscript was not funded.